Clinical Corner
Pilot Training Program Aims to Improve Oncologists' LGBTQ+ Literacy
Pilot training program aims to improve oncologists' LGBTQ+ literacy
According to the American Cancer Society, people in the LGBTQ+ community face certain health disparities, which are often rooted in barriers to care and lack of comfort in health care settings. Low rates of health insurance (as many health insurance policies do not cover unmarried partners), fear of discrimination and negative experiences with heath care providers deters some LGBTQ+ patients from seeking medical care and routine screenings.
When combined with an increased prevalence for certain risk factors, such as drug and alcohol use, LGBT+ populations also have potentially greater risks for several types of cancer. For example:
• Gay and bisexual men are at a greatly increased risk of human papillomavirus (HPV)-associated anal cancer.
• Gay and bisexual women have an increased risk of breast cancer linked to high rates of smoking, obesity, and alcohol use. Women who haven’t had children and haven’t breast-fed, and are older when they first give birth — all factors more likely to affect gay and bisexual women – are also at a slightly higher risk of breast cancer.
• Transgender women on hormone therapy have increased odds of breast cancer, but the overall risk is not as high as it is for the general female population.
• Gay and bisexual men are the population most affected by HIV. Some evidence suggests that men with HIV, especially those with AIDS, are at greater risk of testicular cancers.
A recent study that surveyed nearly 200 oncologists’ attitudes and practice behaviors regarding LGBTQ+ health found that while many oncologists said they were willing to treat and be listed as an LGBTQ+ -friendly provider, many of them weren’t necessarily proficient in inclusive treatment. For example, only 26 percent of oncologists surveyed said they ask for a patient’s sexual orientation and only 46 percent thought that knowing the sexual orientation of their patient was important.
So while most oncologists tend to have positive feelings toward those in the LGBTQ+ community, many of them aren’t necessarily educated on how to properly make LGBTQ+ people feel welcome and comfortable in a medical setting. This can deter members of the LGBTQ+ community from seeking proper help.
These treatment disparities and lack of knowledge within the oncology community inspired investigators from the UF Health Cancer Center, the Sylvester Comprehensive Cancer Center in Miami, and the H. Lee Moffitt Cancer Center & Research Institute in Tampa to create a pilot program to train oncologists on how to approach treatment for those who are LGBTQ+ . The course, called Curriculum for Oncologists on LGBT populations to Optimize Relevance and Skills, or COLORS, is an online LGBTQ+ cultural competency training for oncologists.
Clinical Trial Highlight: Refractory Cancers
This issue of the UFHCC Connection highlights clinical trials currently recruiting patients with refractory malignancies.
Questions about how to send a patient? Please contact the Clinical Trials Office at cancer-center@ufl.edu or 352.273.8675
This phase II/III study investigates whether the combination of cediranib and olaparib compared to cediranib or olaparib alone or standard of care chemotherapy in women with recurrent platinum-resistant or refractory ovarian, fallopian tube, or primary peritoneal cancer improves progression free survival.
Principal Investigator: Merry Markham, M.D., cell: 352.262.1072
This open-label, single arm study is investigating the use of niraparib (an oral PARPinhibitor) in patients with tumors known to have mutations in BAP1 and a variety of other DNA damage response pathway genes. The primary aim is to determine the objective response rate of patients with BAP1 and other DDR repair pathway deficiencies. Cohorts include the histologies above (regardless of mutation) as well as any tumor histology witha confirmed DDR repair pathway mutation.
Principal Investigator: Thomas George, M.D., cell: 352.339.6672
This is an investigator-initiated clinical trial that is based on the discovery of the importance of the Metnase complex in repairing chemotherapy-related DNA damage in leukemia. Ciprofloxacin has been identified as a metnase inhibitor that chemosensitizes leukemic myeloblasts to etoposide chemotherapy. The primary aims are to determine the maximum tolerated dose of ciprofloxacin that can be given in combination with a fixed dose of etoposide and determine the efficacy of the combination treatment in adults with resistant AML.
Principal Investigator: Randy Brown, M.D., cell: 859.221.6828